Allergy Therapeutics
Biomarker data confirm VLP Peanut hypoallergenicityAllergy Therapeutics
Strong FY21 trading, but pipeline set to drive futureAllergy Therapeutics
FY21 pre-close update ahead of market expectationsAllergy Therapeutics
G309 exploratory grass trial on course for H221 read-outAllergy Therapeutics
Record revenues demonstrate resilience of operationsAllergy Therapeutics
Robust growth, pipeline progress, and cash positionAllergy Therapeutics
Imperial peanut allergy biomarker study underwayAllergy Therapeutics
Innovative G309 exploratory grass trial startsAllergy Therapeutics
Strong performances against strategic goals